EnGene Therapeutics starts BLA submission for detalimogene in 4Q 2026
EnGene Therapeutics initiated its BLA submission for detalimogene, planned for 4Q 2026.
Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
1 result loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
EnGene Therapeutics initiated its BLA submission for detalimogene, planned for 4Q 2026.